- Home
- BFRI vs ICU Comparison
BFRI vs ICU Comparison
Compare BFRI & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BFRI | ICU |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3M | 13.8M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BFRI | ICU |
|---|---|---|
| Price | $1.42 | $3.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.75 | N/A |
| AVG Volume (30 Days) | ★ 537.6K | 70.1K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 67.70 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,705,000.00 | $1,234,000.00 |
| Revenue This Year | $14.36 | $53.00 |
| Revenue Next Year | $16.98 | $50.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 11.75 | ★ 814.07 |
| 52 Week Low | $0.57 | $0.22 |
| 52 Week High | $1.52 | $5.38 |
Technical Indicators
Market Signals| Indicator | BFRI | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 70.12 | 42.71 |
| Support Level | $0.77 | $2.21 |
| Resistance Level | N/A | $4.96 |
| Average True Range (ATR) | 0.09 | 0.24 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 71.62 | 28.09 |
Price Performance
Historical ComparisonAbout BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.